Physician profile
Robert Chen
NPI 1487636486
$7,134.01
in general payments reported to CMS, 2019-2025
25 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $423 · 2021: $678 · 2022: $824 · 2023: $1,206 · 2024: $923 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,864.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,743.86 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Abbvie INC. | $791.41 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Johnson & Johnson Surgical Vision, INC. | $777.56 | 2019-2025 | Veritas Vision System, Tecnis Iol, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $556.38 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $453.32 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $409.03 | 2019-2023 | |
| Allergan, INC. | $398.50 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $373.08 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $313.61 | 2019-2020 | |
| Ocular Therapeutix, INC. | $276.77 | 2020-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $220.86 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $204.92 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $177.59 | 2019-2021 | |
| Shire North American Group INC | $111.05 | 2019 | |
| Thea Pharma INC. | $47.56 | 2024-2025 | Iyuzeh |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $46.45 | 2024-2025 | Triesence, Vevye |
| Rayner Intraocular Lenses Limited | $44.64 | 2022-2024 | Rayone Aspheric, Omidria, Rayone Emv |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Omeros Corporation | $33.93 | 2019-2021 | |
| Inspire Medical Systems, INC. | $23.75 | 2023 | Inspire |
| Biotissue Holdings INC. | $23.71 | 2025 | |
| Mallinckrodt Hospital Products INC. | $19.57 | 2022 | |
| Mallinckrodt Enterprises LLC | $16.61 | 2019 | |
| Horizon Therapeutics Plc | $16.46 | 2021 | |
| Dompe US, INC. | $14.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.